AMENDMENT No. 3 to the NON-EXCLUSIVE LICENSE AGREEMENT Dated 6 February 2012 Between LONZA SALES AG and FIVE PRIME THERAPEUTICS, INC. and BIOWA, INC.Non-Exclusive License Agreement • November 6th, 2019 • Five Prime Therapeutics, Inc. • Pharmaceutical preparations
LONZA SALES AG, a limited company incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland, (“Lonza" and together with BioWa, the “Licensor”)
September 19, 2019 Aron M. Knickerbocker VIA EMAIL DELIVERYSeparation Agreement • November 6th, 2019 • Five Prime Therapeutics, Inc. • Pharmaceutical preparations
This letter sets forth the substance of the separation agreement (the “Agreement”) that Five Prime Therapeutics, Inc. (the “Company”) is offering to you in connection with your employment transition.
Amendment No. 4 to the Non-Exclusive License AgreementNon-Exclusive License Agreement • November 6th, 2019 • Five Prime Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 4 to the Non-Exclusive License Agreement (this “Amendment No. 4”), effective August 22, 2019 (the “Fourth Amendment Effective Date”), is made and entered into by and among Five Prime Therapeutics, Inc., a Delaware corporation (“Licensee”), BioWa, Inc., a Delaware corporation (“BioWa”), and Lonza Sales AG, a Swiss corporation (“Lonza” and, together with BioWa, the “Licensor”).
